True Leaf Pet Receives National Animal Supplement Council (NASC) Certification (news with additional features)

DGAP-News: True Leaf Medicine International Ltd. / Key word(s): Regulatory Approval/Interim Report

25.06.2018 / 13:10

The issuer is solely responsible for the content of this announcement.


True Leaf Pet Receives National Animal Supplement Council (NASC) Certification

The company’s hemp-based pet supplements will be showcased with the NASC Quality Seal this week at SuperZoo – North America’s premier pet retail event

See also PDF with product picture.

VERNON, BCJune 25, 2018 – True Leaf Medicine International Ltd. (“True Leaf“) (CSE: MJ) (FSE: TLA) (OTCQB: TRLFF), a plant-forward wellness brand for people and their pets, announced today it has received National Animal Supplement Council (NASC) certification for its True Hemp(TM) line of hemp-seed based pet supplements.

The NASC Quality Seal program was developed after the U.S. Food and Drug Administration’s 21CFR111 regulations for human dietary supplements, and the Food Safety Modernization Act, to give buyers and pet parents peace of mind that the products they are giving their beloved pets have passed rigorous certification standards.

True Leaf received the NASC Seal after successfully passing a thorough quality audit and documentation review. As part of the certification, NASC ensures stringent ingredient qualification, quality production processes, adverse event reporting procedures, continuous product and data monitoring, and allowable product claims.

The newly certified True Hemp(TM) products will be on display this week at SuperZoo, North America’s most-attended pet business event, being held June 26-28, 2018, at Mandalay Bay in Las Vegas, Nevada.

“NASC is one of the highest-level certifications in the pet industry,” said Darcy Bomford, Founder and Chief Executive Officer of True Leaf. “Our True Hemp(TM) products will now display the NASC Seal meaning True Leaf has committed to the highest current standards of quality and safety in the animal supplement industry today.”

True Leaf Pet, a division of True Leaf, pioneered hemp-seed based pet supplements that provide calming support, promote hip and joint health, and help immune and heart function. The company’s True Hemp(TM) line is one of the first hemp-seed based pet products to be marketed worldwide.

True Hemp(TM) dog chews, dental sticks, and supplement oils are now sold in more than 1,800 stores across North America and Europe.

True Leaf Pet hemp-seed based pet supplements are also available on Amazon and at www.trueleafpet.com.

Visit the True Leaf Pet team this week at SuperZoo at Booth 1070 in Hall F.

About True Leaf

True Leaf is a plant-forward wellness brand for people and their pets. Founded in 2013, True Leaf has two main operating divisions: True Leaf Medicine Inc. and True Leaf Pet Inc.

True Leaf Medicine Inc. is in the final stages of approval to become a licensed producer of federally-approved medicinal cannabis for the Canadian market. The license is subject to a Health Canada inspection to allow for the production, manufacture, and distribution of cannabis products upon the completion of True Leaf Campus: the company’s cannabis cultivation facility being built in Lumby, British Columbia. Construction is expected to be completed in fall 2018.

Established in 2015, True Leaf Pet Inc. is one of the first companies to market hemp-based products for pets worldwide. The company is initially marketing a line of hemp-seed based supplements for pets. True Hemp(TM) chews, dental sticks, and supplement oils are sold in more than 1,800 stores across North America and Europe.

www.trueleaf.com

About the National Animal Supplement Council (NASC)

The National Animal Supplement Council is a nonprofit industry group dedicated to protecting and enhancing the health of companion animals and horses throughout the U.S. The NASC was formed in 2001 when a complicated and erratic regulatory environment threatened the multibillion-dollar animal supplement industry.

The NASC Quality Seal program was initiated as part of our ongoing effort to improve and standardize the industry. Different from the NASC logo, members must earn permission to display the Quality Seal by agreeing to adhere to NASC’s quality standards, and by submitting to an independent audit to ensure compliance with our rigorous quality system requirements.

When you see the Quality Seal on a product, you can trust it comes from a reputable company that has successfully passed an independent quality audit. Look for the Quality Seal wherever you purchase animal supplements.

www.nasc.cc

Media Contact:

Paul Sullivan
Director, Public Relations
Paul@trueleaf.com
O: 604-685-4742
M: 604-603-7358

Investor Contact:

Kevin Bottomley (Canada)
Director and Corporate Relations
Kevin@trueleaf.com
M: 778-389-9933

Tirth Patel (US)
Edison Advisors
tpatel@edisongroup.com
O: 646-653-7035

Follow True Leaf

twitter.com/trueleafpet

facebook.com/trueleafpet

instagram.com/trueleafpet

Forward-Looking Statements

This news release contains forward-looking statements and management may make additional forward-looking statements in response to your questions. Such written and oral disclosures are made pursuant to the Safe Harbor provision of the Private Securities Litigation Reform Act of 1995 and True Leaf hereby claims such safe harbour protection for all forward-looking statements. True Leaf believes that the expectations reflected in such forward-looking statements are based on reasonable assumptions; however, True Leaf’s actual results and performance and the value of its securities could differ materially from those set forth in the forward-looking statements due to the impact of many factors summarized in the “Risk Factors” section of True Leaf’s Offering Circular Form 1-A filed with the U.S. Securities and Exchange Commission and Canadian securities regulatory authorities and other discussions of risk factors contained in True Leaf’s periodic filings or supplements to the offering circular. True Leaf’s Offering Circular Form 1-A can be found at www.trueleaf.com/pages/investor. Forward-looking statements speak only as of the date they are made. True Leaf undertakes no obligation to update or revise any such information for any reason after the date of this presentation unless required by law.

 


Additional features:

Document: http://n.eqs.com/c/fncls.ssp?u=WRVCOERUQW
Document title: PDF with picture


25.06.2018 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: True Leaf Medicine International Ltd.
32 – 100 Kalamalka Lake Road
V1T 9 G1 Vernon (BC)
Canada
Phone: +17783899933
E-mail: kevin@trueleaf.com
Internet: www.trueleaf.com
ISIN: CA89785C1077, CA89785C1077
WKN: , A0Q3EE
Listed: Regulated Unofficial Market in Berlin, Frankfurt, Munich, Stuttgart; Canadian Venture Exchange

 
End of News DGAP News Service

show this

EVOTEC ACHIEVES SECOND MILESTONE IN DIABETES ALLIANCE WITH SANOFI

DGAP-News: Evotec AG / Key word(s): Miscellaneous

25.06.2018 / 06:59

The issuer is solely responsible for the content of this announcement.


  • COMPANIES ARE AT THE FOREFRONT OF BETA CELL REPLACEMENT THERAPEUTIC RESEARCH FOR DIABETES
  • EVOTEC RECEIVES EUR 3 MILLION PAYMENT FROM SANOFI
  • MILESTONE FURTHER DEMONSTRATES ADVANCEMENT OF EVT INNOVATE INITIATIVE “TARGETBCD”

Hamburg, Germany, 25 June 2018: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced that its strategic alliance (TargetBCD) with Sanofi in the field of diabetes has reached its second beta cell therapy milestone, resulting in a payment of EUR 3 million to Evotec.

This milestone was triggered after Evotec met pre-agreed critical success criteria for a potential manufacturing process for generation of human induced pluripotent stem cell (iPSC)-derived beta cells, including the demonstration of upscaling potential and suitability of the cell product for encapsulated beta cell function in diabetes models. The goal of the collaboration is to develop a beta cell replacement therapy based on beta cells derived from human iPS cells.

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: “Diabetes is one of the major threats to global healthcare with over 420 million people across the globe affected by either type 1 and type 2 diabetes. We are very pleased with the progress we are making towards a potential game changing beta cell therapy approach and remain committed to discover additional treatment options together with our colleagues at Sanofi.”

ABOUT THE EVOTEC SANOFI ALLIANCE IN DIABETES, (TARGET BCD),
EVT INNOVATE
In August 2015, Evotec and Sanofi entered into a strategic alliance to develop a beta cell replacement therapy based on functional human beta cells derived from human stem cells for diabetes. Evotec and Sanofi will also use human beta cells for high-throughput drug screening to identify beta cell active small molecules or biologics. Both companies make significant contributions to this collaboration in terms of expertise, platforms and resources. The collaboration, which is a key value-driving relationship under the company’s EVT Innovate business segment, further enhances and complements Sanofi’s extensive diabetes R&D pipeline and extends Evotec’s metabolic disease and stem cell-based drug discovery programmes.

Evotec is eligible to receive potential pre-clinical, clinical, regulatory and commercial milestones, which could total over EUR 300 million as well as significant royalties and research payments. To date, Evotec has received EUR 9 million in upfront and milestone payments from Sanofi, as well as, substantial research funding.

ABOUT BETA CELLS
Beta cells play a key role in the pathogenesis of diabetes, a condition which currently affects 425 million people worldwide. Beta cells reside in clusters of hormone producing cells (“islets”) within the pancreas. They respond to elevated blood glucose levels (e.g. after a meal) by secreting the glucose lowering hormone insulin. In the type 1 form of diabetes (“T1D”), beta cells are destroyed by the patient’s own immune system. As a result, T1D patients have to follow a life-long regimen of carefully dosed insulin injections. In patients with type 2 diabetes (“T2D”), beta cells are functionally impaired and yet have to work in the presence of metabolic stress and increased work load due to an impaired tissue insulin response. T2D is progressive, and current therapeutic options cannot prevent the deterioration of beta cell function, eventually also creating a need for insulin injections. Despite the fact that insulin treatments are important and widely used for people with diabetes, injections represent a burden to patients. They cannot fully mimic the normal control of blood glucose levels by normal beta cells, which can result in acute and long-term complications. There is an enormous medical need for novel therapeutic options which can restore beta cell mass and thereby reduce or eliminate the need for insulin injections, or which can prevent or reverse the decline in beta cell function in type 2 diabetes.

ABOUT DIABETES
Diabetes mellitus (“Diabetes”) is a chronic incapacitating disease associated with severe lifelong conditions which require intensive monitoring and control, such as cardiovascular diseases, kidney diseases, nerve damage and eye diseases. At present, there is no cure for diabetes and only symptomatic treatment options are available. According to the International Diabetes Federation, approximately 425 million people worldwide had diabetes in 2017 (2015: 415 million). Concerning the diabetes market volume, approximately $ 727 billion was spent on the treatment of diabetes in 2017 (2015: $ 673 billion).

ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic to meet the industry’s need for innovation and efficiency in drug discovery (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, infectious diseases, diabetes and complications of diabetes, pain, inflammation, and oncology and. On this basis, Evotec has built a broad and deep pipeline of more than 80 partnered product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term discovery alliances with partners including Bayer, CHDI, Sanofi and UCB and development partnerships with e.g. Sanofi in the field of diabetes, Pfizer in the field of tissue fibrosis and Celgene in the field of neurodegenerative diseases. For additional information, please go to
www.evotec.com and follow us on Twitter @EvotecAG.

FORWARD LOOKING STATEMENTS
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

Contact Evotec AG:
Gabriele Hansen, VP Corporate Communications & Investor Relations, Phone: +49.(0)40.56081-255, gabriele.hansen@evotec.com


25.06.2018 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: info@evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange

 
End of News DGAP News Service

show this

Zur Rose Group AG successfully issues a public bond of CHF 85 million

EQS Group-News: Zur Rose Group AG / Key word(s): Bond

22.06.2018 / 17:44


Press release
NOT FOR DISTRIBUTION IN THE UNITED STATES

Zur Rose Group AG successfully issues a public bond of CHF 85 million

Today, Zur Rose Group AG successfully placed a CHF 85 million public bond. The bond offers a coupon of 2.50% and has a tenor of 5 years. The bond will be settled on 19 July 2018 following its listing on the SIX Swiss Exchange. The proceeds of the bond will be used by the issuer primarily to finance acquisitions and for general corporate purposes. The final conditions are as follows:

Issuer Zur Rose Group AG
Issue amount CHF 85 million with option to increase
Interest rate (coupon) 2.50% p.a.
Term to maturity 5 years
Issue price 100%
Repayment price 100%
Settlement 19 July 2018
Listing The listing of the bonds on the SIX Swiss Exchange has been applied for
ISIN CH0421460442

The bond was placed under the lead of UBS AG as sole bookrunner, Raiffeisen as joint lead manager and Bank Vontobel as co-manager.

Investor and analyst contact
Marcel Ziwica, Chief Financial Officer
e-mail: ir@zurrose.com, telephone: +41 58 810 11 49

Media contact
Lisa Lüthi, Head of Corporate Communications
e-mail: lisa.luethi@zurrose.com, telephone: +41 52 724 08 14

Agenda
15 August 2018 Half-year report (analyst and media conference)
24 October 2018 Q3 Trading Update

 

Zur Rose Group

Operating under the Zur Rose and DocMorris brands, the Swiss-based Zur Rose Group is Europe’s leading online pharmacy and one of Switzerland’s foremost wholesale suppliers to medical doctors. Through its business model, it helps to ensure safe, reliable and high-quality pharmaceutical care, while also excelling in developing innovative medicines management services to increase the effectiveness of the medication process. This creation of added value, the strong focus on patients and the commitment to supply medication at low cost for the benefit of payors and patients make the Group an important strategic partner for all healthcare stakeholders.

The Zur Rose Group is headquartered in Frauenfeld, from where it also serves the Swiss market. Customers in Germany and Austria are primarily supplied from Heerlen (NL). Furthermore, the Group holds a majority interest in BlueCare in Winterthur, the leading provider of networking systems in the Swiss healthcare market. Employing more than 1000 people at its various locations, Zur Rose Group generated revenue of CHF 983 million in 2017. Zur Rose Group AG’s shares (ticker symbol ROSE, Swiss security no. 4261528, ISIN CH0042615283) are traded on SIX Swiss Exchange. More information at zurrosegroup.com.

Disclaimer

THIS INFORMATION DOES NOT CONSTITUTE AN OFFER OR INVITATION TO SUBSCRIBE FOR OR PURCHASE ANY SECURITIES. IT IS NOT BEING ISSUED IN COUNTRIES WHERE THE PUBLIC DISSEMINATION OF THE INFORMATION CONTAINED HEREIN MAY BE RESTRICTED OR PROHIBITED BY LAW. IN PARTICULAR, THIS INFORMATION IS NOT BEING ISSUED IN THE UNITED STATES OF AMERICA AND SHOULD NOT BE DISTRIBUTED TO U.S. PERSONS OR PUBLICATIONS WITH A GENERAL CIRCULATION IN THE UNITED STATES. ANY NON-COMPLIANCE WITH SUCH RESTRICTIONS MAY RESULT IN AN INFRINGEMENT OF U.S. SECURITIES LAWS. SECURITIES OF ZUR ROSE AG (“COMPANY”) ARE NOT BEING PUBLICLY OFFERED OUTSIDE OF SWITZERLAND. IN PARTICULAR, THE SECURITIES OF THE COMPANY HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE U.S. SECURITIES LAWS AND MAY NOT BE OFFERED, SOLD OR DELIVERED WITHIN THE UNITED STATES OR TO OR FOR THE ACCOUNT OF U.S. PERSONS EXCEPT IN AN “OFFSHORE TRANSACTION” IN ACCORDANCE WITH REGULATION S UNDER THE SECURITIES ACT. THIS DOCUMENT DOES NOT CONSTITUTE A PROSPECTUS ACCORDING TO ART. 652A OR ART. 1156 OF THE SWISS CODE OF OBLIGATIONS OR ART. 27 ET SEQ. OF THE SIX SWISS EXCHANGE LISTING RULES.


End of Corporate News


Language: English
Company: Zur Rose Group AG
Walzmühlestrasse 60
8500 Frauenfeld
Switzerland
Phone: +41 52 724 08 14
Internet: www.zurrosegroup.com
ISIN: CH0199729366, CH0042615283
Listed: SIX Swiss Exchange

 
End of News EQS Group News Service

show this

PAION AG RAISES EUR 5.2 MILLION IN PRIVATE PLACEMENT

PAION AG / Key word(s): Capital Increase

PAION AG RAISES EUR 5.2 MILLION IN PRIVATE PLACEMENT

21-Jun-2018 / 17:53 CET/CEST

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP – a service of EQS Group AG.

The issuer is solely responsible for the content of this announcement.


NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL

AD-HOC ANNOUNCEMENT
INSIDE INFORMATION ACCORDING TO ARTICLE 17 MAR

PAION AG RAISES EUR 5.2 MILLION IN PRIVATE PLACEMENT

– Financière Arbevel invests EUR 5.2 million

Aachen (Germany), 21 June 2018 – The Specialty Pharma Company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard: PA8) announces that it will issue 2.6 million new shares in a private placement excluding shareholder subscription rights. All shares will be placed with Financière Arbevel, a French institutional investor, at a price of EUR 2.00 per share.

PAION will use the proceeds of the transaction to prepare the necessary work for the submission of the EU market approval dossier for remimazolam.

The capital increase consists of approximately 4% of PAION’s current registered share capital. Following registration of the capital increase, the registered share capital will amount to EUR 63,720,046.00.

The new shares will be admitted to trading on the regulated market of the Frankfurt Stock Exchange.

End of inside information

Contact
Ralf Penner
Vice President Investor Relations/Public Relations
PAION AG
Martinstrasse 10-12
52062 Aachen – Germany
Phone: +49 241 4453-152
E-mail: r.penner@paion.com
www.paion.com

Disclaimer:

This release contains certain forward-looking statements concerning the future business of PAION AG. These forward-looking statements contained herein are based on the current expectations, estimates and projections of PAION AG’s management as of the date of this release. They are subject to a number of assumptions and involve known and unknown risks, uncertainties and other factors. Should actual conditions differ from the Company’s assumptions, actual results and actions may differ materially from any future results and developments expressed or implied by such forward-looking statements. Considering the risks, uncertainties and other factors involved, recipients should not rely unreasonably upon these forward-looking statements. PAION AG has no obligation to periodically update any such forward-looking statements to reflect future events or developments.

This publication constitutes neither an offer to sell nor a solicitation to buy any securities. The securities have already been sold.

This release may not be published, distributed or transmitted in the United States, Canada, Australia, Japan or any other jurisdiction in which the distribution or release would be unlawful. This release does not constitute an offer of securities for sale or a solicitation of an offer to purchase securities (the “Shares“) of PAION AG (the “Company“) in the United States, Germany or any other jurisdiction. The Shares may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the “Securities Act“). The Shares have not been, and will not be, registered under the Securities Act.


21-Jun-2018 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: PAION AG
Martinstr. 10-12
52062 Aachen
Germany
Phone: +49 (0)241-4453-0
Fax: +49 (0)241-4453-100
E-mail: info@paion.com
Internet: www.paion.com
ISIN: DE000A0B65S3
WKN: A0B65S
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange

 
End of Announcement DGAP News Service

show this

Beiersdorf Aktiengesellschaft: Changes on the Executive Board

Beiersdorf Aktiengesellschaft / Key word(s): Change of Personnel

Beiersdorf Aktiengesellschaft: Changes on the Executive Board

21-Jun-2018 / 11:54 CET/CEST

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP – a service of EQS Group AG.

The issuer is solely responsible for the content of this announcement.


Changes on the Executive Board

The Supervisory Board of Beiersdorf Aktiengesellschaft, Hamburg, and the Company’s Chairman of the Executive Board, Stefan F. Heidenreich, have reached an amicable agreement at today’s Supervisory Board meeting that he will resign from the Executive Board when his current term of office ends on December 31, 2019. Stefan F. Heidenreich will vacate his post earlier, if and when the Supervisory Board appoints a successor.

The Supervisory Board discussed the further development of the successful “Blue & Beyond” strategy, focused on Skin Care, including succession and corporate planning supported by growth investments as from 2019, also in preparation for the annual strategy and planning meetings in September and December 2018.

The Supervisory Board additionally assigned Executive Board member Stefan De Loecker – currently in charge of the “Near East/Americas” regions – the board responsibility for “Planning, Strategy and Corporate Development”, as deputy of the Chairman of the Executive Board, as from July 1, 2018.

Contact:
Dr. Jens Geißler
Head of Investor Relations
Tel.: +49 (40) 4909 5000
Fax: +49 (40) 4909 18 5000

Inken Hollmann-Peters
Vice President Corporate Communications
Tel.: +49 (40) 4909 2001
Fax: +49 (40) 4909 2516


21-Jun-2018 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Beiersdorf Aktiengesellschaft
Unnastraße 48
20245 Hamburg
Germany
Phone: +49 (0)40 4909-0
Fax: +49 (0)40 4909-34 34
E-mail: kontakt@Beiersdorf.com
Internet: www.Beiersdorf.com
ISIN: DE0005200000
WKN: 520000
Indices: DAX
Listed: Regulated Market in Frankfurt (Prime Standard), Hamburg; Regulated Unofficial Market in Berlin, Dusseldorf, Hanover, Munich, Stuttgart, Tradegate Exchange

 
End of Announcement DGAP News Service

show this

RESOLUTIONS OF THE ANNUAL GENERAL MEETING 2018 OF EVOTEC AG

DGAP-News: Evotec AG / Key word(s): AGM/EGM

20.06.2018 / 15:57

The issuer is solely responsible for the content of this announcement.


  • APPROVAL OF ALL AGENDA ITEMS WITH CLEAR MAJORITIES
  • CONVERSION OF THE COMPANY INTO EUROPEAN COMPANY (SE) APPROVED 

 
Hamburg, Germany, 20 June 2018:
Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced that its shareholders approved all proposals the Company’s Management put to vote at the Company’s Annual General Meeting 2018 with the required majorities.

The Management Board presented the Company’s progress in the year 2017 and provided the shareholders with an update and outlook regarding future developments of the Company in their presentation “Scientific Excellence meets Operational Excellence”.

The strategy and its execution by the members of the Management Board and the Supervisory Board for the fiscal year 2017 were supported and approved. Furthermore, shareholders at the Annual General Meeting 2018 voted to support the conversion into a European Company with a majority of 99.96%. With this step, Evotec AG will be renamed Evotec SE with the registered seat and headquarters remaining in Hamburg, Germany, after finalising the mandatory negotiation process regarding the future arrangements for employee involvement. This conversion reflects the continuing international focus of the Evotec Group, which has grown considerably in recent years with subsidiaries in France, Germany, Italy, Switzerland, the United Kingdom and the USA.

The Annual General Meeting also approved the appointment of Ernst & Young GmbH Wirtschaftsprüfungsgesellschaft, Hamburg, as the auditor for fiscal year 2018. At the ordinary Annual General Meeting 2018 of Evotec AG, 50.84% of the voting capital was present.

More information on the Company’s Annual General Meeting including the voting results on all agenda items can be found on https://evotec.com/en/invest/annual-general-meeting.


ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic to meet the industry’s need for innovation and efficiency in drug discovery (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology and infectious diseases. On this basis, Evotec has built a broad and deep pipeline of more than 80 partnered product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term discovery alliances with partners including Bayer, CHDI, Sanofi or UCB and development partnerships with e.g. with Sanofi in the field of diabetes, with Pfizer in the field of tissue fibrosis and Celgene in the field of neurodegenerative diseases. For additional information please go to www.evotec.com and follow us on Twitter @EvotecAG.
 
FORWARD LOOKING STATEMENTS
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

Contact Evotec AG:
Gabriele Hansen, VP Corporate Communications & Investor Relations, Phone: +49.(0)40.56081-255, gabriele.hansen@evotec.com


20.06.2018 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: info@evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange

 
End of News DGAP News Service

show this

B.R.A.I.N. Biotechnology Research And Information Network AG: Green Mining – BRAIN AG and CyPlus GmbH develop disruptive technologies for biological processing of precious metal ores

DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG / Key word(s): Miscellaneous/Sustainability

20.06.2018 / 08:29

The issuer is solely responsible for the content of this announcement.


Green Mining
BRAIN AG and CyPlus GmbH develop disruptive technologies for biological processing of precious metal ores

  • Industrially relevant production of precious metals realized on the metric ton scale, even after scale-up of bio-based method
  • Precious-metal enrichment using microorganisms from the BRAIN BioArchives
  • Expansion of the CyPlus product portfolio for Green Mining
  • Market launch of initial products expected in the course of 2019

The bioeconomy company BRAIN AG and CyPlus GmbH have announced the development of an initial range of market-relevant products for the global mining industry. This work has been carried out as part of a multi-year collaboration between the companies in the area of biological ore processing to extract gold and silver. On the basis of successful laboratory research up to the 100-liter scale, the partners then succeeded in scaling up the process to the metric ton level last October, thus reaching an important milestone in the last stage towards market maturity. The bio-based process could produce the desired precious metals from ores in industrially relevant yields, even for throughputs on the metric ton scale. The method is now being further improved for industrial application and this process is sufficiently advanced for the partners to expect the market launch of the first range of products as early as 2019.

The extraction of precious metals from the ores is based on the use of naturally occurring and enhanced microorganisms from the BRAIN BioArchives. During the ongoing collaboration, the partners very soon reached the goal of identifying a variety of microorganisms that, having highly specific adhesion effects, give the gold and silver-bearing minerals a new physical property. This effect can be exploited to separate gold or silver specifically from gangue and enrich it in an integrated process step.

“Our research aims at developing bio-based methods that could offer innovative and sustainable processes for green mining in global markets for ore processing,” says Stefan Welbers, Senior Vice President and General Manager of CyPlus GmbH. “For this reason we’ve continuously kept the technical requirements and structural conditions in mines in mind. In the foreseeable future, for example, we’ll be able to offer mine operators the possibility of integrating advanced biotechnological methods into their current processes without significant investment costs or delays in operation. In this way, we’re expanding our technology portfolio to include biological components for efficient and eco-friendly processing of precious metals.”

Dr. Guido Meurer, member of the Management Board and Unit Head Producer Strain Development at BRAIN AG, says: “We’re delighted – and proud – that the BRAIN and CyPlus interdisciplinary team has succeeded in establishing a groundbreaking biological process for a new processing technology and developing it to high product maturity in just a few years. With our processes for Green Mining it will be possible in the future to exploit ore deposits containing precious metals even in regions where the conventional processes are out of the question. Green Mining is an increasingly important issue and an attractive field of business also in view of the increasing scarcity of raw materials.”

The partners have already filed a patent for the bio-based method, which describes the special microorganisms possessing selectively adhesive properties that can be used to enrich precious metals from ores.

Under the mining program, BRAIN is also researching into biological solutions for what is known as Urban Mining, where precious metals are obtained from side streams and waste streams such as slags, ashes, and electronic scrap. The BRAIN BioXtractor (see www.brain-biotech.de/en/bioxtractor) has been established as a demo system for this purpose.

 

About BRAIN

B.R.A.I.N. Biotechnology Research and Information Network AG (BRAIN AG; ISIN DE0005203947 / WKN 520394) is one of Europe’s leading technology companies in the field of industrial biotechnology, the core discipline of Bioeconomy. As such, BRAIN identifies previously untapped, efficient enzymes, microbial producer organisms or natural substances from complex biological systems that can be put to industrial use. The innovative solutions and products developed by help of this “Toolbox of Nature” are successfully applied in the chemistry, the cosmetics and the food industries. BRAIN’s business model is based on two pillars – BioScience and BioIndustrial. The BioScience segment comprises its frequently exclusive collaboration business with industrial partners. BioIndustrial comprises the development and commercialization of BRAIN’s own products and active product components. Further information is available at www.brain-biotech.de/en.
 

About CyPlus

CyPlus is a globally established company in cyanides. The Evonik subsidiary provides innovative products, technologies and services to customers in the mining, chemical, pharmaceutical, and surface treatment industries. The company meets the extensive and strict requirements of the international mining industry as a supplier of cyanides in accordance with the provisions of the “International Cyanide Management Code” (ICMC). Production sites in Europe as well as sales and distribution offices on all continents provide customers swift and reliable service. CyPlus regards itself as a pacesetter of progress and sustainability. Further information is available at www.cyplus.com.

BžRžAžIžN
Biotechnology Research
And Information Network AG
Darmstädter Str. 34-36
64673 Zwingenberg, Germany
www.brain-biotech.de/en
 
Media Contact
Thomas Deichmann
Head of Public Relations
Tel.: +49-(0)-6251-9331-72
E-Mail: td@brain-biotech.de
 
Investor Relations Contact
Dr. Martin Langer
Executive Vice President
Corporate Development
Tel.: +49-(0)-6251-9331-16
E-Mail: ir@brain-biotech.de
 
 
CyPlus GmbH
Rodenbacher Chaussee 4
63457 Hanau-Wolfgang, Germany
www.cyplus.com
 
Contact
Frank Ladwig
Marketing Manager
Technologies & Services
Tel.: +49-6181-59-6944
E-Mail: frank.ladwig@cyplus.com
 

Disclaimer

This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN AG and are based on information currently available to the management. Forward-looking statements are not guarantees of future performance and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. There are numerous factors which could influence the future performance by and future developments at BRAIN AG and the BRAIN group of companies. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, and other factors. BRAIN AG does not undertake any obligation to update or revise any forward-looking statements.


20.06.2018 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: B.R.A.I.N. Biotechnology Research And Information Network AG
Darmstädter Straße 34-36
64673 Zwingenberg
Germany
Phone: +49 (0) 62 51 / 9331-0
Fax: +49 (0) 62 51 / 9331-11
E-mail: ir@brain-biotech.de
Internet: www.brain-biotech.de
ISIN: DE0005203947
WKN: 520394
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange

 
End of News DGAP News Service

show this

Biotest AG: Biotest AG opens third plasma collection centre in Czech Republi

DGAP-News: Biotest AG / Key word(s): Miscellaneous

20.06.2018 / 07:00

The issuer is solely responsible for the content of this announcement.


/

PRESS RELEASE

Biotest AG opens third plasma collection centre in Czech Republic

– 19 plasma collection centres in Europe to ensure long-term plasma supply

Dreieich, 20 June 2018. Biotest received an operating permit for its third plasma collection centre in Czech Republic from the country’s national public health authority SUKL. The centre is located in Brno the south-eastern part of the country. Biotest has thus completed the expansion of the centre in Brno already planned in the acquisition phase of Cara Plasma s.r.o. on schedule.

“With the third plasma collection centre in the Czech Republic we continued the expansion plan of Cara Plasma s.r.o. With the donated plasma, we can produce life-saving medications for critically ill patients. My thanks also go to our team in the Czech Republic, which opened two new plasma centres in the first half of 2018”, stated Dr Martin Reinecke, Senior Vice President Global Plasma Alliances and Protein Supply of Biotest AG.

The collected plasma is processed only by Biotest AG at Dreieich, Germany. Regular audits in Czech Republic ensure that the strict legal and internal quality requirements are met.

About human blood plasma
Human blood plasma is a raw material used to produce plasma derived products, which are used to treat various illnesses of the immune system, the blood system, as well as in emergency medicine. Biotest ranks as one of the world’s sixth largest plasma protein product manufacturing groups. Biotest is one of the world’s six largest manufacturers of plasma protein products.

About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus which are produced by recombinant technologies. Biotest has more than 1,600 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.

IR contact
Dr. Monika Buttkereit
phone: +49-6103-801-4406
email: investor.relations@biotest.de

PR contact
Dirk Neumüller
phone: +49-6103-801-269
email: pr@biotest.com

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com

Ordinary shares: securities’ ID No. 522720; ISIN DE0005227201
Preference shares: securities’ ID No. 522723; ISIN DE0005227235
Listing: Frankfurt (Prime Standard)
Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate

Disclaimer
This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.

 


20.06.2018 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Germany
Phone: 0 61 03 – 8 01-0
Fax: 0 61 03 – 8 01-150
E-mail: investor_relations@biotest.de
Internet: http://www.biotest.de
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange

 
End of News DGAP News Service

show this

Eckert & Ziegler is Manufacturing Partner for Bayer’s Innovative Targeted Thorium Conjugates in Europe

DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Contract

19.06.2018 / 14:29

The issuer is solely responsible for the content of this announcement.


Berlin, 19 June 2018. Eckert & Ziegler AG, a specialist for scientific, medical, and industrial applications of radioisotopes, has been selected as manufacturing partner for clinical supply of Bayer’s innovative Targeted Thorium Conjugates (TTCs) in Europe. TTCs are a versatile, next-generation targeted alpha therapy (TAT). The approach uses tumor targeting molecules such as antibodies that carry alpha-particle emitting Thorium-227 to the tumor. TTCs have the potential to be used in a broad range of tumors, and also for patients who are refractory to chemotherapy or conventional targeted oncologics. Bayer has established scalable Good Manufacturing Practices (GMP) processes for the alpha-emitter Thorium-227. Eckert & Ziegler will provide the infrastructure for handling, manufacture and distribution of the TTCs for the purpose of clinical trial testing in Europe.

‎”We are delighted to have been selected as a partner for this interesting and important product platform,” says Dr. André Heß, Member of the Executive Board of Eckert & Ziegler and Head of the Radiopharma Segment. “The decision demonstrates how well our Radiopharma Segment can support the requirements of innovative partners by the provision of exceptional radiopharmaceutical expertise, all of which is backed-up by a world-wide logistics infrastructure. We are excited about the potential of this innovative platform technology as Thorium-227 can be coupled with various biomolecules addressing different tumor types.”

About Eckert & Ziegler
Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700) is one of the world’s largest providers of isotope technology for radiation therapy and nuclear medicine and has around 800 employees worldwide. It globally provides nuclear medicine institutions with synthesis technology, quality control instruments, and pharmaceutical grade radioisotopes, among them Yttriga(R), a precursor for Yttrium based oncology products, and GalliaPharm(R); a Gallium-68 radionuclide generator for diagnostic applications.
Contributing to saving lives.

Contact:
Eckert & Ziegler AG
Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com


19.06.2018 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Eckert & Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Germany
Phone: 49 30 941084-138
Fax: 49 30 941084-112
E-mail: karolin.riehle@ezag.de
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange

 
End of News DGAP News Service

show this

Reporting of Stabilisation Transactions

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE.


Initial Public Offering of Polyphor Ltd.

Reporting of stabilisation transactions by UBS AG, Switzerland acting as stabilisation agent (pursuant to Art. 126 letter d Financial Market Infrastructure Ordinance, FMIO)

 

Transaction

Quantity

Price (CHF)

Trade date / Time (CEST)

Buy

4’508

38.00

20180515-09:17

Buy

60

38.00

20180515-09:17

Buy

2’400

38.00

20180515-09:19

Buy

2’500

38.00

20180515-09:19

Buy

427

38.00

20180515-09:19

Buy

8’073

38.00

20180515-09:19

Buy

347

38.00

20180515-09:19

Buy

4’653

38.00

20180515-09:19

Buy

410

38.00

20180515-09:20

Buy

2’655

38.00

20180515-09:20

Buy

3’000

38.00

20180515-10:56

Buy

243

38.00

20180515-10:56

Buy

2’000

38.00

20180515-10:56

Buy

1’257

38.00

20180515-10:56

Buy

2’000

38.00

20180515-10:56

Buy

3’243

38.00

20180515-10:56

Buy

1’757

38.00

20180515-10:56

Buy

243

38.00

20180515-10:56

Buy

3’257

38.00

20180515-10:56

Buy

5’000

37.99

20180515-11:05

Buy

1’743

38.00

20180515-10:56

Buy

3’257

38.00

20180515-10:56

Buy

1’742

38.00

20180515-10:56

Buy

258

38.00

20180515-10:56

Buy

2’316

38.00

20180515-10:56

Buy

1’512

37.88

20180515-11:12

Buy

2’488

37.94

20180515-11:01

Buy

6’200

37.99

20180515-11:07

Buy

5’000

37.98

20180515-11:07

Buy

200

37.94

20180515-11:02

Buy

253

37.94

20180515-11:02

Buy

1’000

37.98

20180515-11:08

Buy

142

37.99

20180515-11:06

Buy

50

37.99

20180515-11:06

Buy

540

37.98

20180515-11:08

Buy

2’500

37.98

20180515-11:08

Buy

12’158

37.50

20180515-11:23

Buy

864

37.50

20180515-11:23

Buy

136

37.50

20180515-11:23

Buy

31

38.00

20180515-10:56

Buy

9’850

38.00

20180515-10:56

Buy

8’310

38.00

20180515-10:56

Buy

1’809

38.00

20180515-10:56

Buy

220

37.88

20180515-10:59

Buy

2’047

37.94

20180515-11:10

Buy

2’478

37.94

20180515-11:10

Buy

2’500

37.90

20180515-11:10

Buy

1’000

37.89

20180515-11:10

Buy

1’500

37.89

20180515-11:10

Buy

2’780

37.88

20180515-11:11

Buy

2’863

37.88

20180515-11:11

Buy

960

37.98

20180515-11:09

Buy

1’000

37.88

20180515-11:11

Buy

1’000

37.88

20180515-11:11

Buy

7’641

38.00

20180515-10:56

Buy

10’390

38.00

20180515-10:56

Buy

9’750

38.00

20180515-10:56

Buy

7’219

38.00

20180515-10:56

Buy

4’031

38.00

20180515-10:56

Buy

272

38.00

20180515-10:48

Buy

2’222

38.00

20180515-10:48

Buy

2’778

38.00

20180515-10:48

Buy

1’178

38.00

20180515-10:48

Buy

881

38.00

20180515-10:48

Buy

1’869

38.00

20180515-10:55

Buy

1’281

38.00

20180515-10:55

Buy

5’719

38.00

20180515-10:55

Buy

2’000

38.00

20180515-10:55

Buy

2’000

38.00

20180515-10:55

Buy

2’002

37.32

20180516-17:31

Buy

4’198

37.32

20180516-17:31

Buy

2’300

37.32

20180516-17:31

Buy

1’500

37.32

20180516-17:31

Buy

989

38.00

20180516-09:41

Buy

1’649

38.00

20180516-09:07

Buy

58

38.00

20180516-09:07

Buy

550

38.00

20180516-09:07

Buy

1’279

38.00

20180516-09:07

Buy

800

38.00

20180516-09:07

Buy

96

38.00

20180516-11:42

Buy

800

38.00

20180516-11:42

Buy

104

38.00

20180516-11:42

Buy

2’008

38.00

20180516-09:07

Buy

125

38.00

20180516-11:39

Buy

1’257

38.00

20180516-11:17

Buy

1’796

38.00

20180516-11:17

Buy

134

38.00

20180516-11:35

Buy

1’314

38.00

20180516-09:57

Buy

1’422

38.00

20180516-09:39

Buy

497

38.00

20180516-11:41

Buy

315

38.00

20180516-11:41

Buy

188

38.00

20180516-11:41

Buy

106

38.00

20180516-11:41

Buy

303

38.00

20180516-11:41

Buy

363

38.00

20180516-11:31

Buy

289

38.00

20180516-11:31

Buy

170

38.00

20180516-09:38

Buy

451

38.00

20180516-11:31

Buy

300

38.00

20180516-11:30

Buy

67

38.00

20180516-09:48

Buy

60

38.00

20180516-11:30

Buy

179

38.00

20180516-11:30

Buy

521

38.00

20180516-11:30

Buy

54

38.00

20180516-11:30

Buy

762

38.00

20180516-09:46

Buy

238

38.00

20180516-09:46

Buy

978

38.00

20180516-09:46

Buy

2’680

38.00

20180516-09:46

Buy

800

38.00

20180516-09:46

Buy

405

38.00

20180516-09:46

Buy

81

38.00

20180516-11:51

Buy

67

38.00

20180516-09:50

Buy

117

38.00

20180516-11:58

Buy

269

38.00

20180516-09:38

Buy

339

38.00

20180516-09:38

Buy

42

38.00

20180516-09:38

Buy

586

38.00

20180516-09:47

Buy

315

38.00

20180516-09:47

Buy

69

38.00

20180516-09:46

Buy

67

38.00

20180516-09:37

Buy

200

38.00

20180516-11:56

Buy

134

38.00

20180516-11:54

Buy

817

38.00

20180516-09:49

Buy

400

38.00

20180516-09:10

Buy

270

38.00

20180516-09:10

Buy

2’492

38.00

20180516-09:03

Buy

147

38.00

20180516-09:49

Buy

202

38.00

20180516-09:47

Buy

592

38.00

20180516-09:09

Buy

134

38.00

20180516-11:54

Buy

69

38.00

20180516-11:54

Buy

799

38.00

20180516-09:09

Buy

800

38.00

20180516-09:09

Buy

1’279

38.00

20180516-09:09

Buy

201

38.00

20180516-09:50

Buy

719

38.00

20180516-11:49

Buy

500

38.00

20180516-09:44

Buy

305

38.00

20180516-09:43

Buy

114

38.00

20180516-09:07

Buy

1’527

38.00

20180516-09:07

Buy

59

38.00

20180516-09:07

Buy

789

38.00

20180516-09:07

Buy

800

38.00

20180516-09:07

Buy

1’079

38.00

20180516-09:07

Buy

200

38.00

20180516-09:07

Buy

800

38.00

20180516-09:07

Buy

164

38.00

20180516-09:55

Buy

632

38.00

20180516-11:44

Buy

91

38.00

20180516-10:08

Buy

134

38.00

20180516-09:38

Buy

145

38.00

20180516-09:35

Buy

178

38.00

20180516-11:39

Buy

210

38.00

20180516-10:08

Buy

248

38.00

20180516-10:08

Buy

1’031

38.00

20180516-10:08

Buy

969

38.00

20180516-10:08

Buy

614

38.00

20180516-09:35

Buy

573

38.00

20180516-09:35

Buy

800

38.00

20180516-09:35

Buy

179

38.00

20180516-09:35

Buy

430

38.00

20180516-09:35

Buy

1’072

38.00

20180516-09:42

Buy

168

38.00

20180516-11:44

Buy

776

38.00

20180516-11:39

Buy

364

38.00

20180516-10:07

Buy

225

38.00

20180516-11:17

Buy

22

38.00

20180516-11:17

Buy

942

38.00

20180516-11:17

Buy

210

38.00

20180516-11:16

Buy

86

38.00

20180516-11:16

Buy

278

38.00

20180516-11:16

Buy

499

38.00

20180516-11:16

Buy

67

38.00

20180516-09:38

Buy

2’590

35.40

20180517-17:31

Buy

1’410

35.40

20180517-17:31

Buy

536

37.49

20180517-09:00

Buy

182

37.49

20180517-09:00

Buy

260

37.49

20180517-09:00

Buy

1’972

37.49

20180517-09:00

Buy

500

37.49

20180517-09:00

Buy

50

37.49

20180517-09:00

Buy

1’500

37.49

20180517-09:00

Buy

410

35.78

20180518-09:27

Buy

476

35.78

20180518-09:27

Buy

998

35.78

20180518-09:27

Buy

166

35.40

20180518-09:01

Buy

544

35.78

20180518-09:27

Buy

2

35.40

20180518-09:01

Buy

1

35.40

20180518-09:01

Buy

998

35.78

20180518-09:27

 

Disclaimer

These materials may not be published, distributed or transmitted in the United States, Canada, Australia or Japan. These materials do not constitute an offer of securities for sale or a solicitation of an offer to purchase securities (the “Securities”) of Polyphor Ltd. (the “Company”) in the United States, Switzerland or any other jurisdiction. The Securities of the Company may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the “Securities Act”). The Securities of the Company have not been, and will not be, registered under the Securities Act. Any sale in the United States of the securities mentioned in this communication will be made solely to “qualified institutional buyers” as defined in, and in reliance on, Rule 144A under the Securities Act.

This publication constitutes neither an offer to sell nor a solicitation to buy any securities. This document is not an issuance or listing prospectus or a similar document in the sense of article 652a, article 752 and/or article 1156 of the Swiss Code of Obligations or articles 27 et seq. of the Listing Rules of the SIX Swiss Exchange Ltd. and was not reviewed by any competent authority. Any offer of securities of the Company will be made solely by means of, and on the basis of, an offering memorandum that will contain detailed information about the Company and its management as well as risk factors and financial statements. Any person considering the purchase of any securities of the Company must inform itself independently based solely on such offering memorandum (including any supplement thereto).

This document does not constitute an “offer of securities to the public” within the meaning of Directive 2003/71/EC of the European Union, as amended (the “Prospectus Directive”) of the securities referred to herein in any member state of the European Economic Area (the “EEA”). Any offers of the securities referred to in this document to persons in the EEA will be made pursuant to an exemption under the Prospectus Directive, as implemented in member states of the EEA, from the requirement to produce a prospectus for offers of the Securities. In any EEA Member State that has implemented the Prospectus Directive, this document is only addressed to and is only directed at qualified investors in that Member State within the meaning of the Prospectus Directive, i.e., only to investors who can receive the offer without an approved prospectus in such EEA Member State.

In the United Kingdom, this document is only being distributed to and is only directed at persons who (i) are investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the “Order”) or (ii) are persons falling within Article 49(2)(a) to (d) of the Order (high net worth companies, unincorporated associations, etc.) (all such persons together being referred to as “Relevant Persons”). This document is directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this document relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.

This communication may contain statements about the future that use words such as, for example, “believe”, “assume”, “expect”, “forecast”, “project”, “may”, “could”, “might”, “will” and other similar expressions. Such statements about the future are subject to known and unknown risks, uncertainties, and other factors, which can cause the true results, financial situation, development or performance of the Company to differ significantly from that which is expressly or implicitly assumed in these statements. In view of these uncertainties, the reader should not depend on this type of statement about the future. The Company gives no undertaking whatever to update such statements regarding the future, or to adapt them to future events or developments.